Our people are on a mission to cure infectious diseases and make a real difference in the lives of people around the world. Are you up for the challenge? Discover why you should join …

Dec 31, 2024 · SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by developing innovative therapies.

At SCYNEXIS, we are bringing a ground-breaking class of drugs to the battle by developing innovative products that have the strength, safety and versatility to defeat even the most insidious fungal diseases.

BREXAFEMME, a one-day oral treatment for vaginal yeast infection, is the first FDA-approved indication of the ibrexafungerp development pipeline U.S. commercial launch expected in the second half of 2021 in partnership with Amplity Health, marking the evolution of SCYNEXIS to a commercial-stage antifungal company

At SCYNEXIS, we believe that our innovative fungerp class of antifungals could be essential therapy in the treatment of multiple serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and more.

JERSEY CITY, N.J., March 12, 2025 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today reported financial results for the year ended December 31, 2024.

SCYNEXIS Initiates Dosing in Phase 1 Trial of SCY-247, a Second-Generation Fungerp Candidate for Invasive Fungal Infections

SCYNEXIS regularly presents key infectious disease study data at top medical meetings.

SCYNEXIS regularly presents key infectious disease study data at top medical meetings.

JERSEY CITY, N.J., Oct. 03, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced upcoming presentations of preclinical efficacy and pharmacokinetic data on its second-generation fungerp candidate ...